Lifestyle
- Regular exercise
- Stress management
- Adequate sleep
Lymphocytes · T-cells · B-cells
Lymphocyte count measures the number of lymphocytes in the blood, reflecting the status of the immune system.
Reference ranges may vary slightly based on laboratory standards and patient demographics.
Lymphocytes, abbreviated as LYMPH, are a type of white blood cell that play a crucial role in the immune system. They are primarily responsible for identifying and neutralizing pathogens such as viruses and bacteria. Lymphocytes are categorized into three main types: T-cells, B-cells, and natural killer cells, each with distinct functions in immune response. Researchers have observed that T-cells are involved in cell-mediated immunity, while B-cells are responsible for antibody production. Clinically, lymphocyte levels are significant indicators of immune system health. Elevated lymphocyte counts can suggest infections, autoimmune disorders, or certain cancers, while low counts may indicate immunodeficiency, bone marrow disorders, or the effects of chemotherapy. In the context of athletic performance and biohacking, maintaining optimal lymphocyte levels is essential for efficient recovery and resistance to infections, which can otherwise impair training and performance. Longevity studies suggest that a balanced immune response, as indicated by stable lymphocyte levels, may contribute to a longer, healthier life. However, researchers found that lymphocyte levels can be influenced by various factors, including stress, recent infections, and medications. Time-of-day variations and fasting status may also affect lymphocyte counts, necessitating standardized testing conditions for accurate assessment.
Klinische Bedeutung
Elevated lymphocyte levels may indicate infections, autoimmune diseases, or lymphoproliferative disorders. Reduced levels can suggest immunodeficiency, bone marrow suppression, or effects of immunosuppressive therapy.
Progressively rising lymphocyte levels may suggest an ongoing immune response or the development of a lymphoproliferative disorder. Re-test in 4 weeks if levels remain elevated.
Progressively falling lymphocyte levels could indicate immunosuppression or bone marrow dysfunction.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a healthcare provider before making significant lifestyle changes, especially if underlying health conditions are present.
Lymphocyte counts can vary throughout the day; consistent timing is recommended for repeat tests.
Testing Frequency
Annually for healthy adults, more frequently if monitoring specific conditions.
May affect
Current research suggests that the optimal strategies for quantifying tumour-infiltrating lymphocytes (TILs) and understanding the specific roles of different TIL subpopulations remain debated, with a lack of standardized methods and functional profiling. Emerging research directions include the exploration of neoantigen-specific lymphocytes in circulation and their potential as biomarkers for personalized therapies. However, clinical questions regarding the precise mechanisms of TIL dysfunction and their predictive value in various treatment contexts remain unanswered.
1,163
Total Citations
7
Human/RCT
6.2
Avg. Influence
2022
Latest
Researchers investigated the presence of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. They found that PD-1 expression on circulating lymphocytes could identify T cells targeting tumor-specific neoantigens, providing a noninvasive approach to develop personalized cancer therapies. This study identified unique neoantigen-specific T cells in the blood of some patients.
Researchers examined the role of T cells in cancer immunotherapy, focusing on their potential to enhance anti-tumor responses. They identified various therapeutic strategies, including checkpoint blockade and CAR T cell therapy, aimed at activating T lymphocytes against tumors. The study discusses the challenges and opportunities in optimizing T cell-mediated therapies.
This review discussed the role of exosomal PD-L1 in cancer and its implications for immunotherapy. Researchers highlighted how exosomal PD-L1 can inhibit T cell activity in the tumor microenvironment and emphasized its potential as a biomarker for cancer treatment. The study also addressed challenges in researching exosomal PD-L1.
This study explored the mechanisms behind drug-induced lupus, a condition linked to certain medications. Researchers observed that autoimmunity may be triggered by oxidative metabolites of drugs, affecting lymphocytes. The findings suggest that prolonged drug exposure can lead to autoimmunity without direct drug-specific immune responses.
This study examined the role of tumour-infiltrating lymphocytes (TILs) in cancer immunotherapy. Researchers found that TILs are crucial for immune-mediated tumor elimination and highlighted the need for standardized methods to study their various subpopulations and functions. The research also discussed the potential of TILs as biomarkers for immunotherapy response.
Researchers identified dysfunctional CD16+ CD8 T cells in smokers using single-cell analyses. They found that smoking is associated with an increase in differentiated T cells and a decrease in naïve T cells, indicating immune aging. This study suggests that smoking may lead to immune dysregulation, impacting overall health.
This review focused on intestinal intraepithelial lymphocytes (IELs) and their diverse roles in immune defense. Researchers highlighted that IELs are crucial for gut health and may be involved in diseases like celiac disease and inflammatory bowel diseases. The study emphasized the need for further understanding of IEL dynamics and their clinical significance.
This review examined the impact of FOXP3 regulatory T cells on breast cancer prognosis. Researchers found that the presence of FOXP3+ Tregs can correlate with both poor and good prognoses, indicating a complex role in tumor immunity. The study calls for further research to clarify the relationship between FOXP3 expression and breast cancer outcomes.
Researchers studied the effects of ofatumumab therapy on lymphocytes in multiple sclerosis patients. They found a rapid depletion of CD20+ lymphocytes, including a complete loss of CD3+CD20+ T lymphocytes, within a week of treatment. This indicates that ofatumumab not only targets B cells but also affects a small subset of T cells.
This review assessed the use of MRI and laboratory biomarkers in monitoring disease-modifying therapies in multiple sclerosis. Researchers found that lymphocyte counts and other laboratory markers can inform treatment efficacy and safety, highlighting the importance of a biomarker-enhanced monitoring strategy for better patient outcomes.
Research publications about Lymphozyten over time
9totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer